A randomized, double-blind, placebo-controlled trial of intravenous alpha-1 antitrypsin for ARDS secondary to COVID-19
Med(2022)
摘要
•Patients with COVID-19-associated ARDS were randomized to receive IV AAT or placebo•Patients receiving IV AAT had decreased IL-6, sTNFR1, and CRP at 1 week•Differential glycosylation of endogenous AAT was preserved in the treatment group•Treatment with IV AAT was safe and well tolerated
更多查看译文
关键词
coronavirus,COVID-19,alpha-1 antitrypsin,interleukin-6,clinical trial,randomized control trial,inflammation,cytokines,acute respiratory distress syndrome
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要